biostudies-literatureBortoletto ASEleanor Schwartz Charitable TrustBaylor College of Medicine Medical Scientist Training ProgramNICHD NIH HHSNHLBI Division of Intramural ResearchNational Heart, Lung, and Blood InstituteNHLBI NIH HHSNational Institutes of HealthMike Hogg FundNIDDK NIH HHSSmall Business Innovation ResearchRobertson Therapeutic Development FundNational Institute of Child Health and Human DevelopmentNIH HHSe2202342https://www.ebi.ac.uk/biostudies/studies/S-EPMC9731688biostudies-literatureUnknown9(34)Type 2 diabetes mellitus (T2D) is a major public health concern and is characterized by sustained hyperglycemia due to insulin resistance and destruction of insulin-producing β cells. One pathological hallmark of T2D is the toxic accumulation of human islet amyloid polypeptide (hIAPP) aggregates. Monomeric hIAPP is a hormone normally co-secreted with insulin. However, increased levels of hIAPP in prediabetic and diabetic patients can lead to the formation of hIAPP protofibrils, which are toxic to β cells. Current therapies fail to address hIAPP aggregation and current screening modalities do not detect it. Using a stabilizing capping protein, monoclonal antibodies (mAbs) can be developed against a previously nonisolatable form of hIAPP protofibrils, which are protofibril specific and do noAdvanced science (Weinheim, Baden-Wurttemberg, Germany)Human Islet Amyloid Polypeptide (hIAPP) Protofibril-Specific Antibodies for Detection and Treatment of Type 2 Diabetes.PMC9731688SBIR R43DK125161R43DK125161R43 DK125161T32 HL092332R01HD099252R01HD098131R01 HD098131R01 HD099252Trout GBonito-Oliva AKazmi MAHouser BLSakmar TPParchem RJWeyburne EBortoletto ASGong JGraham WVfalseHuman Islet Amyloid Polypeptide (hIAPP) Protofibril-Specific Antibodies for Detection and Treatment of Type 2 Diabetes.Type 2 diabetes mellitus (T2D) is a major public health concern and is characterized by sustained hyperglycemia due to insulin resistance and destruction of insulin-producing β cells. One pathological hallmark of T2D is the toxic accumulation of human islet amyloid polypeptide (hIAPP) aggregates. Monomeric hIAPP is a hormone normally co-secreted with insulin. However, increased levels of hIAPP in prediabetic and diabetic patients can lead to the formation of hIAPP protofibrils, which are toxic to β cells. Current therapies fail to address hIAPP aggregation and current screening modalities do not detect it. Using a stabilizing capping protein, monoclonal antibodies (mAbs) can be developed against a previously nonisolatable form of hIAPP protofibrils, which are protofibril specific and do no2022-01-01T00:00:00Z2022 Dec2026-07-14T16:57:17.033Z2026-06-21T03:07:51.258ZS-EPMC97316883625790510.1002/advs.202202342